Teva sues to head off generic Zoloft challengers

Share this article:
Teva Pharmaceuticals is suing several other generic drug companies that seek to challenge its position as the lone maker of non-branded Zoloft. Companies named in the suits include Novartis AG’s Sandoz and Lupin Laboratories. Zoloft (sertraline), an antidepressant marketed by Pfizer, lost patent protection in June. Teva began selling a generic version in September and has sole rights to do so until Feb. 6, the expiration date for its 180-day exclusivity period on producing sertraline. The FDA gave its tentative nod for several others to receive approval to make generic copies on that date, including Sandoz and Lupin. The Teva suits, filed in New Jersey and Delaware, target would-be sellers of generic Zoloft, plus companies that make the active ingredient, according to Bloomberg. Other companies Teva is suing are Apotex, Cipla, Cadila Healthcare's Zydus-Cadila Healthcare, Merck KGaA's Genpharm, and Watson Pharmaceuticals's Andrx, as well as manufacturers Invagen Pharmaceuticals, Hetero Drugs and Torrent Pharmaceuticals, according to court records cited by Bloomberg.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.